The 4th Annual Antibody Summit: Bispecifics & Multispecifics is dedicated to the progress in discovery, development and therapeutics of novel protein therapeutics.
The 4th Annual Antibody Summit: Bispecifics & Multispecifics covers topics such as:
- Emerging approaches, science and tech to engineer and to bring to market more targeted, stable extended half-life, and functional multispecifics
- CMC strategies for developing manufacturing processes and product quality characterization of bispecifics / multispecifics
- Imaging, theranostic, and other new applications of bispecifics in oncology and beyond
- Advanced analytical development and characterization for novel protein formats
- Accelerating translation and clinical development progress of bispecific antibody and combination therapies
The 4th Annual Antibody Summit: Bispecifics & Multispecifics brings together attendees involved or interested in:
- Analytical & Formulation
- Antibody Discovery
- Biologics
- Bioassay
- CD3
- Cancer
- Central Nervous System (CNS) / Neuroscience
- Clinical trials / Development
- EGFR
- Drug Development
- Genetics
- Fc
- In Silico Modelling / Quantitative Science
- Immunogenicity
- Multispecific Antibody
- Manufacturing
- Preclinical Models
- Oncology
- Protein Chemistry
- Process Development / Developability
- Theranostics
- T-cell
- Yield
- Toxicities / Toxicology
- Antibody Engineering
- Biochemistry
- Blood Brain Barrier
- Cancer Immunotherapies
- Bispecifics
- CMC / Regulatory
- Checkpoint
- Drug Targets / Targets Selection
- Combination Therapies
- FIH
- Ex Vivo Assay
- Immunology
- Imaging
- Monoclonal Antibodies
- Mab
- Pharmacokinetics (PK)
- Neuroscience
- Protein
- Process / Manufacturing Quality
- Target Toxities
- Screening / Modelling
- Tumours
- Therapeutic Antibodies
